T Cell-Engaging BiTE Antibodies Specific for EGFR Potently Eliminate KRAS- And BRAF-mutated Colorectal Cancer Cells

Proceedings of the National Academy of Sciences of the United States of America - United States
doi 10.1073/pnas.1000976107
Full Text
Abstract

Available in full text

Date
Authors
Publisher

Proceedings of the National Academy of Sciences

Related search

CDX2: A Prognostic Marker in Metastatic Colorectal Cancer Defining a Better BRAF Mutated and a Worse KRAS Mutated Subgroup

Frontiers in Oncology
Cancer ResearchOncology
2020English

Prevalence of KRAS, BRAF, PI3K and EGFR Mutations Among Asian Patients With Metastatic Colorectal Cancer

Oncology Letters
Cancer ResearchOncology
2015English

BRAF-mutated Metastatic Colorectal Cancer Between Past and Future

British Journal of Cancer
Cancer ResearchOncology
2015English

Lauric Acid Can Improve the Sensitization of Cetuximab in KRAS/BRAF Mutated Colorectal Cancer Cells by Retrievable microRNA-378 Expression

Oncology Reports
MedicineCancer ResearchOncology
2015English

Mutation Pattern of KRAS and BRAF Oncogenes in Colorectal Cancer Patients

Neoplasma
Cancer Research
2012English

Pilot Trial of Combined BRAF and EGFR Inhibition in BRAF-Mutant Metastatic Colorectal Cancer Patients

Clinical Cancer Research
Cancer ResearchOncology
2015English

Molecular Pathological Epidemiology of Colorectal Cancer in Chinese Patients With KRAS and BRAF Mutations

Oncotarget
Oncology
2015English

BGB-283, a Novel RAF Kinase and EGFR Inhibitor, Displays Potent Antitumor Activity in BRAF-Mutated Colorectal Cancers

Molecular Cancer Therapeutics
Cancer ResearchOncology
2015English

Concomitant Inhibition of Receptor Tyrosine Kinases and Downstream AKT Synergistically Inhibited Growth of KRAS/BRAF Mutant Colorectal Cancer Cells

Oncotarget
Oncology
2016English

Amanote Research

Note-taking for researchers

Follow Amanote

© 2024 Amaplex Software S.P.R.L. All rights reserved.

Privacy PolicyRefund Policy